| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Oncology Research Laboratory, G. Gaslini Children's Hospital, Largo G. Gaslini 5, Genoa 16148 [M. P., P. B., V. C., V. P., L. R., C. R., P. G. M.], and Department of Medical Oncology II, National Cancer Institute, Genoa 16132 [A. D.], Italy
Retinoids exert various important biological effects in the control of normal growth, differentiation, and fetal development. While retinoic acid (RA) has entered clinical trials as a differentiation-promoting agent, it is only recently that the synthetic retinoid N-(4-hydroxyphenyl)retinamide (HPR) has been shown to be of potential clinical interest in cancer chemoprevention and treatment. Since thus far no data exist on the effects of HPR on neural crest cell-derived tumors, we have examined its in vitro effects on neuroblastoma (NB) cell lines and found that at relevant pharmacological concentrations it induces a dose-dependent growth inhibition. The antiproliferative effects of HPR were, in six of six cell lines tested, drastically more potent that those induced by an equimolar dose of RA. Time course growth analysis showed that HPR at 3 x 10-6 M induces a very rapid (24–72 h) fall in thymidine uptake (>90%), whereas at 3 x 10-7 M it exhibits cytostatic effects.
In contrast to RA, HPR did not show morphological changes typical of NB cell maturation nor did it induce the expression of any cytoskeletal protein associated with neuronal differentiation.
DNA flow cytofluorimetric analysis revealed that HPR did not induce an arrest in a specific phase of the cell cycle while triggering apoptosis. This phenomenon was evidenced both by the visualization of "DNA ladders" on gel electrophoresis and by a quantitative assay for evaluating programmed cell death based upon the labeling of DNA breaks with tritiated thymidine. With the latter method, apoptotic cells were detectable as early as 3–6 h after treatment of NB cells with 10-5 M HPR, while more than 50% of cells were apoptotic by 24–72 h following exposure to 3 x 10-6 M HPR. In contrast, RA induced a low rate of apoptosis in NB cells only after 3–5 days.
Time lapse photomicroscopy showed that NB cells treated with HPR underwent a death process highly reminiscent of apoptosis, with progressive condensation of the cytoplasm around the nucleus and intense cell shrinkage. The cells then rounded up and detached from the plate. Furthermore, propidium iodide staining of the DNA showed that a high proportion of cells treated with HPR displayed a small and brightly staining nucleus; chromatin appeared aggregated into dense masses in the nuclear periphery, a typical feature of apoptotic cells.
In conclusion, our study demonstrates that contrary to the differentiation-promoting activity of RA, HPR dramatically suppresses NB cell growth by inducing programmed cell death. Since the peak HPR plasma concentration in patients treated with the drug is superimposable to the dose inducing apoptosis in vitro (i.e., 1–3 x 10-6 M), our results may support the hypothesis of the use of HPR in the treatment of advanced neuroblastoma.
1 This work was partially supported by Italian Association for Cancer Research and by Ricerca Corrente Ministeriale Gaslini.
2 To whom requests for reprints should be addressed.
Received 8/18/94. Accepted 12/16/94.
This article has been cited by other articles:
|
|
 |
|
  D. Marimpietri, C. Brignole, B. Nico, F. Pastorino, A. Pezzolo, F. Piccardi, M. Cilli, D. Di Paolo, G. Pagnan, L. Longo, et al. Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis Clin. Cancer Res., July 1, 2007; 13(13): 3977 - 3988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maurer, O. Kalous, D. W. Yesair, X. Wu, J. Janeba, V. Maldonado, V. Khankaldyyan, T. Frgala, B.-C. Sun, R. T. McKee, et al. Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex Clin. Cancer Res., May 15, 2007; 13(10): 3079 - 3086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Pastorino, C. Brignole, D. Di Paolo, B. Nico, A. Pezzolo, D. Marimpietri, G. Pagnan, F. Piccardi, M. Cilli, R. Longhi, et al. Targeting Liposomal Chemotherapy via Both Tumor Cell-Specific and Tumor Vasculature-Specific Ligands Potentiates Therapeutic Efficacy. Cancer Res., October 15, 2006; 66(20): 10073 - 10082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Brignole, D. Marimpietri, F. Pastorino, B. Nico, D. Di Paolo, M. Cioni, F. Piccardi, M. Cilli, A. Pezzolo, M. V. Corrias, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst, August 16, 2006; 98(16): 1142 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Villablanca, M. D. Krailo, M. M. Ames, J. M. Reid, G. H. Reaman, and C. P. Reynolds Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709) J. Clin. Oncol., July 20, 2006; 24(21): 3423 - 3430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Raffaghello, G. Zuccari, R. Carosio, I. Orienti, and P. G. Montaldo In vitro and In vivo Antitumor Activity of the Novel Derivatized Polyvinyl Alcohol-Based Polymer P10(4). Clin. Cancer Res., June 1, 2006; 12(11): 3485 - 3493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Simile, G. Pagnan, F. Pastorino, C. Brignole, M. R. De Miglio, M. R. Muroni, G. Asara, M. Frau, M. A. Seddaiu, D. F. Calvisi, et al. Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-{kappa}B and Mat1A genes in the early stages of rat liver carcinogenesis Carcinogenesis, February 1, 2005; 26(2): 417 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pastorino, C. Brignole, D. Marimpietri, M. Cilli, C. Gambini, D. Ribatti, R. Longhi, T. M. Allen, A. Corti, and M. Ponzoni Vascular Damage and Anti-angiogenic Effects of Tumor Vessel-Targeted Liposomal Chemotherapy Cancer Res., November 1, 2003; 63(21): 7400 - 7409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Garaventa, R. Luksch, M. S. L. Piccolo, E. Cavadini, P. G. Montaldo, M. R. Pizzitola, L. Boni, M. Ponzoni, A. Decensi, B. D. Bernardi, et al. Phase I Trial and Pharmacokinetics of Fenretinide in Children with Neuroblastoma Clin. Cancer Res., June 1, 2003; 9(6): 2032 - 2039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pastorino, C. Brignole, D. Marimpietri, P. Sapra, E. H. Moase, T. M. Allen, and M. Ponzoni Doxorubicin-loaded Fab' Fragments of Anti-disialoganglioside Immunoliposomes Selectively Inhibit the Growth and Dissemination of Human Neuroblastoma in Nude Mice Cancer Res., January 1, 2003; 63(1): 86 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-G. Kim, K.-R. You, M.-J. Liu, Y.-K. Choi, and Y.-S. Won GADD153-mediated Anticancer Effects of N-(4-Hydroxyphenyl)retinamide on Human Hepatoma Cells J. Biol. Chem., October 4, 2002; 277(41): 38930 - 38938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bruno, C. Tenca, D. Saverino, E. Ciccone, and C. E. Grossi Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment Carcinogenesis, March 1, 2002; 23(3): 447 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-R. You, J. Wen, S.-T. Lee, and D.-G. Kim Cytochrome c Oxidase Subunit III. A MOLECULAR MARKER FOR N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED OXIDATIVE STRESS IN HEPATOMA CELLS J. Biol. Chem., February 1, 2002; 277(6): 3870 - 3877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Schildkraut, B. Calingaert, P. A. Marchbanks, P. G. Moorman, and G. C. Rodriguez Impact of Progestin and Estrogen Potency in Oral Contraceptives on Ovarian Cancer Risk J Natl Cancer Inst, January 2, 2002; 94(1): 32 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Rodriguez, N. P. Nagarsheth, K. L. Lee, R. C. Bentley, D. K. Walmer, M. Cline, R. S. Whitaker, P. Isner, A. Berchuck, R. K. Dodge, et al. Progestin-Induced Apoptosis in the Macaque Ovarian Epithelium: Differential Regulation of Transforming Growth Factor-{beta} J Natl Cancer Inst, January 2, 2002; 94(1): 50 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pagnan, D. D. Stuart, F. Pastorino, L. Raffaghello, P. G. Montaldo, T. M. Allen, B. Calabretta, and M. Ponzoni Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects J Natl Cancer Inst, February 2, 2000; 92(3): 253 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-R. Chen, G. Zhou, and T.-H. Tan c-Jun N-Terminal Kinase Mediates Apoptotic Signaling Induced by N-(4-Hydroxyphenyl)retinamide Mol. Pharmacol., December 1, 1999; 56(6): 1271 - 1279. [Abstract] [Full Text]
|
|
|
|
|
|
V. K. Puduvalli, Y. Saito, R. Xu, G. P. Kouraklis, V. A. Levin, and A. P. Kyritsis Fenretinide Activates Caspases and Induces Apoptosis in Gliomas Clin. Cancer Res., August 1, 1999; 5(8): 2230 - 2235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maurer, L. S. Metelitsa, R. C. Seeger, M. C. Cabot, and C. P. Reynolds Increase of Ceramide and Induction of Mixed Apoptosis/Necrosis by N-(4-Hydroxyphenyl)- retinamide in Neuroblastoma Cell Lines J Natl Cancer Inst, July 7, 1999; 91(13): 1138 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ronca, K. S. Y. Yee, and V. C. Yu Retinoic Acid Confers Resistance to p53-dependent Apoptosis in SH-SY5Y Neuroblastoma Cells by Modulating Nuclear Import of p53 J. Biol. Chem., June 18, 1999; 274(25): 18128 - 18134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Morita and J. L. Tilly Segregation of Retinoic Acid Effects on Fetal Ovarian Germ Cell Mitosis Versus Apoptosis by Requirement for New Macromolecular Synthesis Endocrinology, June 1, 1999; 140(6): 2696 - 2703. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Ferrari, M. Pfahl, and G. Levi Retinoic Acid Receptor gamma 1 (RARgamma 1) Levels Control RARbeta 2 Expression in SK-N-BE2(c) Neuroblastoma Cells and Regulate a Differentiation-Apoptosis Switch Mol. Cell. Biol., November 1, 1998; 18(11): 6482 - 6492. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. C. Rodriguez, D. K. Walmer, M. Cline, H. Krigman, B. A. Lessey, R. S. Whitaker, R. Dodge, and C. L. Hughes Effect of Progestin on the Ovarian Epithelium of Macaques: Cancer Prevention Through Apoptosis? Reproductive Sciences, September 1, 1998; 5(5): 271 - 276. [Abstract] [PDF]
|
|
|
|
|
|
S. V. Yarovoi, X.-P. Lu, N. Picard, D. Rungta, D. Rideout, and M. Pfahl Selective Activation of an Apoptotic Retinoid Precursor in Macrophage Cell Lines J. Biol. Chem., August 14, 1998; 273(33): 20852 - 20859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Liu, S. Takayama, Y. Zheng, B. Froesch, G.-q. Chen, X. Zhang, J. C. Reed, and X.-k. Zhang Interaction of BAG-1 with Retinoic Acid Receptor and Its Inhibition of Retinoic Acid-induced Apoptosis in Cancer Cells J. Biol. Chem., July 3, 1998; 273(27): 16985 - 16992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Spanjaard, M. Ikeda, P. J. Lee, B. Charpentier, W. W. Chin, and T. J. Eberlein Specific Activation of Retinoic Acid Receptors (RARs) and Retinoid X Receptors Reveals a Unique Role for RARgamma in Induction of Differentiation and Apoptosis of S91 Melanoma Cells J. Biol. Chem., July 25, 1997; 272(30): 18990 - 18999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Fanjul, D. Delia, M. A. Pierotti, D. Rideout, J. Qiu, and M. Pfahl 4-Hydroxyphenyl Retinamide Is a Highly Selective Activator of Retinoid Receptors J. Biol. Chem., September 13, 1996; 271(37): 22441 - 22446. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
